GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Median PS Value
中文

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Median PS Value

: $0.00 (As of Today)
View and export this data going back to 2020. Start your Free Trial

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Calliditas Therapeutics AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.562. Calliditas Therapeutics AB's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-04-23), Calliditas Therapeutics AB's share price is $19.19. Calliditas Therapeutics AB's Median PS Value is $0.00. Therefore, Calliditas Therapeutics AB's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Calliditas Therapeutics AB's Median PS Value or its related term are showing as below:

CALT's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.665
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Calliditas Therapeutics AB Median PS Value Historical Data

The historical data trend for Calliditas Therapeutics AB's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only - - - - -

Calliditas Therapeutics AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Calliditas Therapeutics AB's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Calliditas Therapeutics AB Price-to-Median-PS-Value Distribution

For the Biotechnology industry and Healthcare sector, Calliditas Therapeutics AB's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Calliditas Therapeutics AB's Price-to-Median-PS-Value falls into.



Calliditas Therapeutics AB Median PS Value Calculation

Calliditas Therapeutics AB's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=3.562*0
=0.00

10-Year Median PS Ratio is 0.
Calliditas Therapeutics AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.562.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calliditas Therapeutics AB  (NAS:CALT) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Calliditas Therapeutics AB's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=19.19/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calliditas Therapeutics AB Median PS Value Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Traded in Other Exchanges
Address
Kungsbron 1, D5, Stockholm, SWE, SE-111 22
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.